View Transcript

Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart Pump

A three-year, investigator-led, prospective study of Japanese patients who received an Impella® heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock patients. The historic survival rate for cardiogenic shock is approximately 50%.

The interim analysis examined 819 patients treated with Impella for a variety of conditions, including cardiogenic shock and myocarditis, at 109 hospitals in Japan. Overall, investigators conclude the favorable 30-day survival data indicates Impella is a beneficial therapy.

This slide is available for download here.

NPS-939
NPS-942

Subscribe or join the conversation by following us on Twitter: @ProtectedPCI


To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information